Cover Image

Multiple-dose pharmacokinetics of a novel, synthetic trioxane-antimalarial compound 97/78 in rats using LC-MS/MS method

Rajendra Pratap Singh, Sabarinath S., Hari Narayan Kushwaha, Nagsen Gautam, Ram Chandra Gupta, Shio Kumar Singh*

Abstract


Multiple dose pharmacokinetic study was studied in rats following oral dose administration at 47 mg/kg. The pharmacokinetic profile of 97/78 was investigated in form of its completely converted in-vivo active metabolite 97/63 after dose administration. Quantification of metabolite 97/63 in rat plasma was achieved on LC-MS/MS. Chromatographic run time was 4.0 min and the weighted (1/x2) calibration curves were linear over the range 1.56–200ng/ml. After oral administration of 97/78 in rats the peak plasma concentration was observed between 0.75 and 2 h. Compound was rapidly absorbed and declined within 24 h after each dosing.  Multiple maximum concentrations were observed at different time points. Mean Residence Time of 97/63 was observed at 5.06±0.40 h. The terminal elimination half-lives did not significantly change for multiple doses (T1/2, 2.65±0.70 h) in comparison to single-dose (T1/2, 2.80±0.56 h) administration. Also there is no enhancement in AUC values during multiple dose administration, indicating no plasma accumulation of 97/63. There were no significant differences between peak and trough concentrations of 97/63 on days 1, 2, 3, 4 and 5. Trough plasma concentration states that the body systemic exposure is high. The average plasma concentration-time profile of 97/63 confirms no plasma accumulation of 97/63.

Keywords


Antimalarial; LC-MS/MS; Multiple-dose; 97/78; Pharmacokinetics

Full Text:

PDF

References


Winstanley PA, Ward SA and Snow RW. Clinical status and implication of antimalarial drug resistance. Microbe and Infection 2002; 4: 157–164.

World Health Organization, World Malaria Report 2005.

Yikang Wu. How Might Qinghaosu (Artemisinin) and Related Compounds Kill the Intraerythrocytic Malaria Parasite? A Chemist's View. Accounts of Chemical Research 2002; 35: 255-259.

Robert A, Dechy-Cabaret O, Cazelles J and Meunier B. From mechanistic studies on artemisinin derivatives to new modular antimalarial drugs. Accounts of Chemical Research 2002; 35: 167-174.

Cheng F, Luo JS, Zhu W, Gu J, Ji R, Jiang H and Chen K. Molecular docking and 3-D-QSAR studies on the possible antimalarial mechanism of artemisinin analogues. Bioorganic and Medical Chemistry 2002; 10: 2883-2891.

Singh C and Puri SK. Substituted 1,2,4-trioxanes as antimalarial agents and a process of producing the substituted 1,2,4-trioxanes. United State Patent 6316493 B1. 2001.

Singh C, Gupta N and Puri SK. Photo oxygenation of 3-aryl-2-cyclohexenols: synthesis of a new series of antimalarial 1,2,4-trioxanes. Tetrahedron Letters 2005; 46: 205-207.

Griesbeck AG, El Idreesy TT, Hoinck LO, Lex J and Brun R. Novel spiroanellated 1,2,4-trioxanes with high in-vitro antimalarial activities. Bioorganic and Medicinal Chemistry Letters 2005; 15: 595-597.

Singh C, Srivastava NC and Puri SK. Synthesis and antimalarial activity of 6-cycloalkylvinyl substituted 1,2,4-trioxanes. Bioorganic and Medicinal Chemistry Letters 2004; 12: 5745-5752.

Mostafavi SA and Foster RT. Pharmacokinetics of metoprolol enantiomers following single and multiple administration of racemate in rat. International Journal of Pharmaceutics 2000; 202: 97–102.




DOI: http://dx.doi.org/10.21746/ijbio.2014.07.003

Refbacks

  • There are currently no refbacks.




Copyright (c) 2014 International Journal of Bioassays

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

International Journal of Bioassays is a member of the Publishers International Linking Association, Inc. (PILA), CROSSREF and CROSSMARK (USA). Digital Object Identifier (DOI) will be assigned to all its published content.